	US 11,859,187 B2
	Aptamers for personal health care applications
Juan Esteban Velasquez, Cincinnati, OH (US); Spencer Christopher Rupard, Morrow, OH (US); Amy Violet Trejo, Mason, OH (US); Adam Michael Pitz, Morrow, OH (US); Kelly Lee Schmeichel, Cincinnati, OH (US); Erin Nicole Swigart, Morrow, OH (US); and Gregory Allen Penner, London (CA)
Assigned to The Procter & Gamble Company, Cincinnati, OH (US)
Filed by The Procter & Gamble Company, Cincinnati, OH (US)
Filed on Jun. 24, 2021, as Appl. No. 17/356,828.
Claims priority of provisional application 63/043,952, filed on Jun. 25, 2020.
Prior Publication US 2021/0403919 A1, Dec. 30, 2021
Int. Cl. C12N 15/113 (2010.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61K 31/7088 (2006.01); C12Q 1/68 (2018.01)

CPC C12N 15/1138 (2013.01) [A61K 31/7088 (2013.01); A61K 47/549 (2017.08); A61K 47/60 (2017.08); C12N 2310/16 (2013.01); C12N 2310/351 (2013.01); C12N 2320/31 (2013.01); C12N 2320/32 (2013.01)]

24 Claims

1. Aptamer composition comprising at least one oligonucleotide consisting of: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof, wherein the aptamer composition has a binding affinity for intercellular adhesion molecule 1 (ICAM-1) and wherein the aptamer is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1) and wherein the aptamer composition comprises

at least one oligonucleotide selected from the group consisting of oligonucleotides with at least 95% nucleotide sequence identity to sequences selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 200.